Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients

Autor: Stylianos Kakolyris, George Kolios, Anastasios J. Karayiannakis, Evi Lianidou, Eirini Biziota, Ioanna Balgkouranidou, Evangelos Karamitrousis, Nikolaos Xenidis, Helen Bolanaki, K. Amarantidis, Triantafyllia Koukaki, Grigorios Trypsianis
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
Cancer Research
Tumor suppressor gene
Wif-1
03 medical and health sciences
0302 clinical medicine
Stomach Neoplasms
Promoter methylation
medicine
Biomarkers
Tumor
SOXF Transcription Factors
Humans
Epigenetics
Progression-free survival
SOX17
Promoter Regions
Genetic
Gene
RC254-282
Adaptor Proteins
Signal Transducing
business.industry
gastric cancer
Tumor Suppressor Proteins
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Cancer
Methylation
RASSF1A
DNA
Neoplasm
Advanced gastric cancer
DNA Methylation
Middle Aged
medicine.disease
Prognosis
Gene Expression Regulation
Neoplastic
Survival Rate
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Cancer research
Original Article
Female
methylation
business
Cell-Free Nucleic Acids
Follow-Up Studies
Zdroj: Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 20 (2021)
ISSN: 1533-0338
1533-0346
Popis: Epigenetic modification of several genes is a key component in the development of gastric cancer. The methylation status of RASSF1A, SOX17 and Wif-1 genes was evaluated in the cell free circulating DNA of 70 patients with advanced gastric cancer, using methylation-specific PCR. Patients with higher cell-free DNA concentration seem to have lower PFS, than patients with lower cell-free DNA concentration (p = 0.001). RASSF1A was the tumor suppressor gene, most frequently methylated in metastatic gastric cancer patients, followed by SOX17 and Wif-1 (74.3%, 60.0% and 47.1%, respectively). Patients having the SOX17 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p < 0.001). Patients having the Wif-1 promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.001). Patients having the RASSF1A promoter methylated, had lower progression free survival and overall survival, than unmethylated ones (p = 0.004). Promoter methylation of the examined genes was significantly associated with a decrease in progression free survival and overall survival, comparing to that of patients without methylation. Simultaneous methylation of the above genes was associated with even worse progression free survival and overall survival. The methylation of RASSF1A, SOX-17 and Wif-1 and genes, is a frequent epigenetic event in patients with advanced gastric cancer.
Databáze: OpenAIRE
Externí odkaz: